menopause. Menopausal and female climacteric states
Conditions
Interventions
Treatment - Drugs
Placebo
Sponsors
Mashhad University of Medical Sciences, Vice chancellor for research
Eligibility
Sex/Gender
Female
Age
44 Years to 64 Years
Inclusion criteria
Inclusion criteria: postmenopausal status, which was defined as aged between 45-65 with no vaginal bleeding for 1 year no regular ingestion of phytoestrogen or soy-based products ; having a normal mammogram in the last year.The exclusion criteria were : use of any fluoride or bisphosphonates; diseases or medications affecting bone metabolism; Currently (or in the past 6 months) using estrogen or calcitonin; medication for lowering lipids or blood pressure diabetes mellitus; no regular physical exercise or allergy to
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High density lipoprotein (HDL). Timepoint: before and 90 days after treatment. Method of measurement: biochemical test.;Osteoporosis. Timepoint: before intervention and 90 days after intervention. Method of measurement: the dual energy X-ray absorptiometry was utilized to measure bone mineral density (BMD).;Low density lipoprotein (LDL). Timepoint: beforer and after tratment. Method of measurement: biochemical test.;Total cholesterol. Timepoint: before and 90 days after treatment. Method of measurement: biochemical test.;Triglycerides. Timepoint: Before and after 90 days treatment. Method of measurement: biochemical test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Tafaghodi
Mashhad University of Medical Sciences, Vice chancellor for research
Outcome results
None listed